On The Quick
Naloxone Manufacturers Donate 30,000 Free Doses
New surgeon general advisory
In an advisory issued in April, U.S. Surgeon General Jerome Adams affirmed the importance of naloxone in reducing the human cost of our nation’s opioid epidemic. To support that effort, two leading naloxone manufacturers are donating 30,000 doses of the overdose reversal drug for distribution to high-risk patients.
The Recovery Paradox
One of the paradoxes of the opioid crisis is that patients receiving treatment for opioid dependency are at elevated risk of overdose. The pain of withdrawal can tempt patients to relapse, but recovery also reduces their tolerance, which can make “falling off the wagon” extremely hazardous. “People with opioid use disorder are at highest risk for overdose within 30 days of completing treatment, particularly if they are not receiving medication to support their recovery,” explains the surgeon general. Earlier this year, Adams issued an advisory recommending that clinicians provide naloxone to high-risk patients.
As reported in the June issue of Working Nurse, the Canadian province of British Columbia has had great success with its similar take-home naloxone program, which offers the drug for free to high-risk patients and their families and friends.
Free Take-Home Kits
Two of the principal naloxone manufacturers, Adapt Pharma and kaléo, Inc., have signed on to support the surgeon general’s effort. In late April, these manufacturers announced that they would donate 30,000 doses of the drug to the National Council for Behavioral Health. This new program provides two free take-home doses of naloxone to patients undergoing opioid disorder treatment at participating public or nonprofit treatment programs. Adams calls it “an important step in getting naloxone to the people who need it most, when they need it most.” For more information, visit www.thenationalcouncil.org.
This article is from workingnurse.com.